How Can Contingent Valuation Inform the Bioethics Debate? Evidence from a Survey on Hereditary Cancers in France

Christel Protière, Olivier Chanel, Emmanuelle Mouret-Fourme, Claire Julian-Reynier, Catherine Noguès () and Isabelle Coupier
Additional contact information
Emmanuelle Mouret-Fourme: Hôpital René Huguenin [Saint-Cloud] - ICSC - Institut Curie - Saint Cloud
Claire Julian-Reynier: SESSTIM - U912 INSERM - Aix Marseille Univ - IRD - Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale - IRD - Institut de Recherche pour le Développement - AMU - Aix Marseille Université - INSERM - Institut National de la Santé et de la Recherche Médicale
Catherine Noguès: Hôpital René Huguenin [Saint-Cloud] - ICSC - Institut Curie - Saint Cloud
Isabelle Coupier: Unité d'Oncogénétique - CRLCC Val d'Aurelle - Paul Lamarque, Service de génétique médicale [Montpellier] - CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier] - Hôpital Arnaud de Villeneuve [CHU Montpellier] - CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]

Post-Print from HAL

Abstract: BRCA1/2 carriers have a higher risk of developing breast and ovarian cancer at a younger age. Preimplantation genetic diagnosis (PGD) and prenatal diagnosis (PND) are two of the few options available to avoid transmitting the mutation. To inform the bioethics debate about authorization, a contingent valuation survey elicited preferences regarding access to PGD and PND from a sample of 460 unaffected by cancer BRCA1/2 carriers (GENEPSO cohort). We find that the respondents can be classified into three groups: one opposed to PGD/PND (28.3%), one strongly in favour of PGD/PND (45.8%), and one in an intermediate position (25.9%). We look for the determinants of these preferences, especially of the willingness to pay for PGD/PND. Overall, we find that BRCA1/2 carriers support access to PGD/PND, which has implications for recommendations to decision-makers.

Keywords: Economie; quantitative (search for similar items in EconPapers)
Date: 2017-05
References: Add references at CitEc
Citations:

Published in Revue Economique, 2017, 68 (3), pp.379--404. ⟨10.3917/reco.683.0379⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
Journal Article: How Can Contingent Valuation Inform the Bioethics Debate? Evidence from a Survey on Hereditary Cancers in France (2017)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-01589998

DOI: 10.3917/reco.683.0379

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().